Biotech Movers

Updated April 16, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

492 active tickers10 with insider buys25 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
AKRO Akero Therapeutics Inc.	Exited EcoR1 Capital, OrbiMed Advisors +6	5	—	14d Ph3	165
ZBIO Zenas BioPharma, Inc.	New EcoR1 Capital, Rock Springs Capital	1	4 $5.5M	75d Ph3	150
WVE Wave Life Sciences Ltd.	Added RA Capital Management, RTW Investments	2	4 $54.6M	72d Ph2	140
CRNX Crinetics Pharmaceuticals Inc.	Added Baker Bros. Advisors, OrbiMed Advisors +5	3	—	198d Ph2	135
TNGX Tango Therapeutics Inc.	Exited Baker Bros. Advisors, EcoR1 Capital +5	3	—	45d Ph2	130
SYRE Spyre Therapeutics, Inc.	New RA Capital Management, EcoR1 Capital +4	4	—	75d Ph2	130
CNTA Centessa Pharmaceuticals plc	Added Baker Bros. Advisors, Perceptive Advisors +4	2	—	14d Ph2	130
XNCR Xencor Inc.	Trimmed EcoR1 Capital, RA Capital Management +5	3	—	230d Ph2	125
LENZ LENZ Therapeutics, Inc.	Added Rock Springs Capital	3	3 $366K	—	125
DYN Dyne Therapeutics Inc.	Exited EcoR1 Capital, Baker Bros. Advisors +4	2	1 $34K	—	115
COGT Cogent Biosciences Inc.	Exited Baker Bros. Advisors, RA Capital Management +5	2	—	75d Ph2	110
APLS Apellis Pharmaceuticals Inc.	Exited EcoR1 Capital, OrbiMed Advisors +4	3	—	440d Ph2	110
CGON CG Oncology, Inc.	Exited RA Capital Management, OrbiMed Advisors +4	4	—	75d Ph2	110
MLYS Mineralys Therapeutics, Inc.	Added Rock Springs Capital, Tang Capital Management	2	2 $8.8M	—	110
FDMT 4D Molecular Therapeutics, Inc.	Added Baker Bros. Advisors, EcoR1 Capital +3	5	—	75d Ph2	105
ALKS Alkermes plc	Added Baker Bros. Advisors, EcoR1 Capital +4	2	—	75d Ph2	105
PRAX Praxis Precision Medicines, Inc.	Added Baker Bros. Advisors, RA Capital Management +3	3	—	75d Ph3	105
NAMSW NewAmsterdam Pharma Co N.V.	Exited Baker Bros. Advisors, EcoR1 Capital +5	2	—	—	105
IONS Ionis Pharmaceuticals Inc.	Exited EcoR1 Capital, Baker Bros. Advisors +2	3	—	14d Ph3	105
RLAY Relay Therapeutics Inc.	Exited EcoR1 Capital, Perceptive Advisors +4	3	—	—	105
KYMR Kymera Therapeutics Inc.	Exited Redmile Group, EcoR1 Capital +4	2	—	440d Ph2	95
MGNX MACROGENICS INC	Exited EcoR1 Capital, Baker Bros. Advisors +4	1	—	318d Ph2	95
OVID Ovid Therapeutics Inc.	New RA Capital Management, EcoR1 Capital +2	3	—	—	95
GPCR Structure Therapeutics Inc.	Exited RA Capital Management, OrbiMed Advisors +3	6	—	106d Ph2	95
EXAS Exact Sciences Corporation	Exited RA Capital Management, OrbiMed Advisors +4	2	—	243d Ph2	95
ACAD ACADIA Pharmaceuticals Inc.	Exited EcoR1 Capital, RA Capital Management +4	1	—	259d Ph2	95
ATXS Astria Therapeutics Inc.	Exited RA Capital Management, Tang Capital Management +3	4	—	349d Ph3	95
PCVX Vaxcyte Inc.	Trimmed RA Capital Management, OrbiMed Advisors +3	4	—	290d Ph3	95
PRTO Protara Therapeutics, Inc.	Added Baker Bros. Advisors, RA Capital Management +3	2	—	440d Ph3	90
MRSN Mersana Therapeutics Inc.	Exited Baker Bros. Advisors, EcoR1 Capital +4	—	—	—	90
KURA Kura Oncology, Inc.	Exited EcoR1 Capital, RA Capital Management +4	2	—	—	90
ETNB 89bio Inc.	Exited RA Capital Management, Deep Track Capital +3	6	—	—	90
RXDX Prometheus Biosciences Inc.	Exited Driehaus Capital, Perceptive Advisors +2	2	—	14d Ph2	90
VRNA Verona Pharma plc	Exited Baker Bros. Advisors, RA Capital Management +2	2	—	13d Ph2	90
RYTM Rhythm Pharmaceuticals Inc.	Added OrbiMed Advisors, Perceptive Advisors +2	4	—	198d Ph2	90
IRON Disc Medicine Inc.	Added RA Capital Management, OrbiMed Advisors +3	2	—	167d Ph2	90
AUTL Autolus Therapeutics plc	Exited Rock Springs Capital, Deep Track Capital +4	2	—	—	90
BCRX BIOCRYST PHARMACEUTICALS INC	Added Baker Bros. Advisors, RA Capital Management +3	1	—	—	85
ELVN Enliven Therapeutics, Inc.	Added Baker Bros. Advisors, RA Capital Management +2	3	—	—	85
NUVL Nuvalent Inc.	Added RA Capital Management, Deep Track Capital +2	4	—	—	85
OLMA Olema Pharmaceuticals, Inc.	New RA Capital Management, Deep Track Capital +2	2	—	75d Ph3	85
NBIX Neurocrine Biosciences Inc.	Added Rock Springs Capital, Tang Capital Management +1	1	—	14d Ph3	85
TERN Terns Pharmaceuticals Inc.	New Baker Bros. Advisors, OrbiMed Advisors +1	3	—	—	80
CMPS COMPASS Pathways plc	Exited Baker Bros. Advisors, EcoR1 Capital +3	1	—	75d Ph3	80
ARVN Arvinas Inc.	Exited Baker Bros. Advisors, EcoR1 Capital +3	1	—	593d Ph2	80
MDGL Madrigal Pharmaceuticals Inc.	Exited EcoR1 Capital, OrbiMed Advisors +3	1	—	259d Ph3	80
GRAL GRAIL, Inc.	New RA Capital Management, Baker Bros. Advisors +2	2	—	—	80
TVTX Travere Therapeutics Inc.	Exited RA Capital Management, OrbiMed Advisors +3	—	—	75d Ph2	80
ARGX argenx SE	Exited EcoR1 Capital, OrbiMed Advisors +3	2	—	106d Ph2	80
TYRA Tyra Biosciences, Inc.	Exited EcoR1 Capital, OrbiMed Advisors +2	4	—	228d Ph2	80

Showing 50 of 492

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why AKRO is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days, no credit card required.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Want AI context on every signal? Start free trial →